P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS

P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS

Bibliographic Details
Main Authors:	Guenther Koehne, Benjamin Tomlinson, Hyung Suh, Divya Koura, Christina Cho, Nadia M Bambace, Léa Bernard, Nirali N Shah, Roland Walter, John Dipersio, Miguel-Angel Perales, Michael R Loken, Kyle Breitschwerdt, Sritama Nath, Glen Raffel, Brenda W Cooper
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000972472.24418.bc

Similar Items

Structural Characterization of the Aggregates of Gemtuzumab Ozogamicin
by: Qingping Jiang, et al.
Published: (2019-04-01)

Resolution of hypogammaglobulinemia-associated recurrent Campylobacter bacteraemia after hematopoietic cell transplantation (HCT)
by: Emmanouil Karofylakis, MD, et al.
Published: (2025-02-01)

Gemtuzumab ozogamicin is efficacious in attaining complete remission in relapsed/refractory acute leukemia prior to hematopoietic cell transplant: A case series
by: Giancarlo Fatobene, et al.
Published: (2021-10-01)

HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) IN CHILDREN WITH AUTISM SPECTRUM DISORDER: CHALLENGES AND THERAPEUTIC STRATEGIES
by: ASS Ibanez, et al.
Published: (2024-10-01)

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
by: Mahesh Swaminathan, et al.
Published: (2023-02-01)

Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era
by: María Queralt Salas, et al.
Published: (2024-12-01)

sMAdCAM‐1 is decreased after allo‐HCT, along with gut microbiota dysbiosis, and is associated with hematopoietic recovery
by: Karen Fadel, et al.
Published: (2025-01-01)

Humoral and Mucosal Antibody Response to RSV Structural Proteins in RSV-Infected Adult Hematopoietic Cell Transplant (HCT) Recipients
by: Xunyan Ye, et al.
Published: (2021-05-01)

Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come
by: Johann Hitzler, et al.
Published: (2019-01-01)

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
by: Jatinder K. Lamba, et al.
Published: (2021-05-01)

Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
by: Daniil Zaytsev, et al.
Published: (2020-02-01)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
by: Hien K Duong, et al.
Published: (2009-05-01)

Autoimmune Cytopenias in Pediatric Hematopoietic Cell Transplant Patients
by: Jessica A. Neely, et al.
Published: (2019-05-01)

Dental caries as a risk factor for bacterial blood stream infection (BSI) in children undergoing hematopoietic cell transplantation (HCT)
by: Dawud Abduweli Uyghurturk, et al.
Published: (2022-09-01)

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia
by: Michele Gottardi, et al.
Published: (2017-09-01)

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
by: Bo Yu, et al.
Published: (2019-10-01)

A SECOND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT2) MAY CURE MORE THAN 40% PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
by: MF Cardoso, et al.
Published: (2023-10-01)

The Role of T Cells in Hematopoietic Stem Cell Engraftment
by: Elizabeth Hexner
Published: (2006-01-01)

Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms—A Systematic Review
by: Aurelia Collados-Ros, et al.
Published: (2024-01-01)

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancersResearch in Context
by: Livingstone Fultang, et al.
Published: (2019-09-01)

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
by: Jorge E. Cortes, et al.
Published: (2020-10-01)

Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia
by: Petra Hååg, et al.
Published: (2022-06-01)

AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin.
by: David B Rosen, et al.
Published: (2013-01-01)

Post-Transplant Complications in Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT)—A Comparative Analysis of Home Care versus Hospitalized Patients
by: Ana María Garcés-Carrasco, et al.
Published: (2023-12-01)

Maintenance therapy for AML after allogeneic HCT
by: Rahul K. Nayak, et al.
Published: (2022-08-01)

Treatment of AML Relapse After Allo-HCT
by: Jonathan A. Webster, et al.
Published: (2021-12-01)

Gemtuzumab Ozogamicina: uma opção no tratamento de Leucemia mielóide aguda CD33+ Gemtuzumab Ozogamicin: an option in the treatment of acute myeloid leukemia CD33+
by: Celso M. Massumoto, et al.
Published: (2004-12-01)

Isatuximab for Delayed Red Cell Engraftment after Allogeneic Hematopoietic Cell Transplantation
by: Mary Nauffal, et al.
Published: (2024-01-01)

Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia
by: Sule Unal, et al.
Published: (2009-02-01)

Effect and safety of gemtuzumab ozogamicin for the treatment of patients with acute myeloid leukaemia: a systematic review protocol
by: Nor A Muhamad, et al.
Published: (2020-06-01)

BLINATUMOMAB + DONOR LEUKOCYTE INFUSIONS (DLI) CAN BE USED TO PREVENT THE RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT)
by: CNM Breviglieri, et al.
Published: (2024-10-01)

A mindfulness-based stress management program for caregivers of allogeneic hematopoietic stem cell transplant (HCT) patients: Protocol for a randomized controlled trial.
by: Min-Jeong Yang, et al.
Published: (2022-01-01)

Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation
by: Weijie Cao, et al.
Published: (2022-11-01)

Comparison of two spirometry reference equations in predicted FEV1 quantification and its effects on hematopoietic cell transplantation‐specific comorbidity index (HCT‐CI)
by: Ana L. Ramos, et al.
Published: (2022-07-01)

Quickly attainable and highly engrafting hematopoietic stem cells
by: Hal E. Broxmeyer
Published: (2019-08-01)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT) IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE (SCD): A FEASIBLE CURATIVE OPTION WITH HLA-IDENTICAL OR HAPLOIDENTICAL DONORS
by: RV Gouveia, et al.
Published: (2024-10-01)

Correction: A mindfulness-based stress management program for caregivers of allogeneic hematopoietic stem cell transplant (HCT) patients: Protocol for a randomized controlled trial.
by: Min-Jeong Yang, et al.
Published: (2022-01-01)

Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population
by: Praveen Shukla, et al.
Published: (2020-07-01)

Structural and dynamic basis of substrate permissiveness in hydroxycinnamoyltransferase (HCT)
by: Levsh, Olesya, et al.
Published: (2020)

Reliability of HCT-based Soil Water Retention Curves
by: Bagheri Meghdad, et al.
Published: (2023-01-01)